Recent advances in management of COVID-19: A review

Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection

(2021) Myron S. Cohen   NEW ENGLAND JOURNAL OF MEDICINE

Fluvoxamine, melatonin and COVID-19

(2021) George M. Anderson   PSYCHOPHARMACOLOGY

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

(2021) Paul-Albert Koenig et al.   SCIENCE

Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19)

(2021) Salma Bessalah et al.   3 Biotech

Monoclonal Antibodies as Neurological Therapeutics

(2021) Panagiotis Gklinos et al.   Pharmaceuticals

Pineal hormone melatonin as an adjuvant treatment for COVID‑19 (Review)

(2021) Marilena Vlachou et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Monoclonal Antibodies for COVID-19

(2021) Elizabeth C. Lloyd et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

(2021) Ivan O. Rosas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

(2021) Phillip Pymm et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

(2021) Robert W. Malone et al.   Frontiers in Pharmacology

Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China

(2020) Jin-jin Zhang et al.   ALLERGY

The outbreak of COVID-19

(2020) Yi-Chi Wu et al.   Journal of the Chinese Medical Association

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

(2020) Xiao-Wei Xu et al.   BMJ-British Medical Journal

Melatonin for the treatment of sepsis: the scientific rationale

(2020) Ruben Manuel Luciano Colunga Biancatelli et al.   Journal of Thoracic Disease

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

(2020) Canrong Wu et al.   Acta Pharmaceutica Sinica B

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing

(2020) Oleg O. Glebov   FEBS Journal

Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

(2020) Daniel E. Freedberg et al.   GASTROENTEROLOGY

COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal

(2020) Hasan K. Siddiqi et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series

(2020) Tobias Janowitz et al.   GUT

COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks

(2020) Markus Blaess et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Monoclonal Antibodies for Prevention and Treatment of COVID-19

(2020) Mary Marovich et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

(2020) Fatemeh Heidary et al.   JOURNAL OF ANTIBIOTICS

Clinical trial to test the efficacy of melatonin in COVID‐19

(2020) Dario Acuña‐Castroviejo et al.   JOURNAL OF PINEAL RESEARCH

COVID-19: Melatonin as a potential adjuvant treatment

(2020) Rui Zhang et al.   LIFE SCIENCES

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

(2020) Jiangdong Huo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

(2020)   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 Sepsis and Microcirculation Dysfunction

(2020) Antonio Colantuoni et al.   Frontiers in Physiology

The COVID-19 Cytokine Storm; What We Know So Far

(2020) Dina Ragab et al.   Frontiers in Immunology

Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19

(2020) Russel J. Reiter et al.   Frontiers in Medicine

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

(2020) Jeffrey F. Mather et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)

(2020) Juliana Cepelowicz Rajter et al.   CHEST

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19

(2020) Bruno M. Tomazini et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Role of melatonin in the treatment of COVID-19; as an adjuvant through cluster differentiation 147 (CD147)

(2020) Ahmet Ozer Sehirli et al.   MOLECULAR BIOLOGY REPORTS

Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients

(2020) Reed B. Hogan II et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain

(2020) Xiaojing Chi et al.   Nature Communications

Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease

(2020) Hamidreza Samaee et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19

(2020) Eric J. Lenze et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

(2020) Carlos Salama et al.   NEW ENGLAND JOURNAL OF MEDICINE

Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection

(2020) Niyati Desai et al.   Nature Communications

Immune suppression in the early stage of COVID-19 disease

(2020) Wenmin Tian et al.   Nature Communications

Applications of Nanobodies

(2020) Serge Muyldermans   Annual Review of Animal Biosciences

Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis

(2019) Dorian A. Rosen et al.   Science Translational Medicine

Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis

(2019) Magdalene M. Assimon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases

(2019) Daniel A. Ryskamp et al.   Frontiers in Neuroscience

Clinical Pharmacology of Corticosteroids

(2018) Dennis M Williams   Respiratory Care

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

(2017) F. Peyvandi et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Nanobodies and their potential applications

(2013) Gholamreza Hassanzadeh-Ghassabeh et al.   Nanomedicine

Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation

(2013) Marco Peviani et al.   NEUROBIOLOGY OF DISEASE

Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): A Novel Pharmacological Group of Drugs with Broad Clinical Applications

(2010) Johannes Kornhuber et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY